The Next Growth Curve: How Biopharma Can Win in Developing Markets
Biopharmaceutical companies are operating in an increasingly fragmented environment, with global dynamics shifting rapidly. Developed markets that for long offered predictable growth are now slowing, reflecting not only the stabilisation typical of mature healthcare systems but also mounting pricing and budgetary pressures.
In the US and Western Europe, healthcare spend as a share of GDP is pressing affordability limits, driving payers to extract savings across drug budgets to create headroom for next‑generation biologics and cell and gene therapies.
At the same time, momentum is shifting to emerging markets—particularly across the Middle East and Africa—where 2025 delivered the largest global pharma expansion, with IQVIA noting countries such as Saudi Arabia helped drive 18% year‑on‑year regional growth. Through 2030, “pharmerging” markets are projected to add $121 billion in medicine spending. Capturing this growth requires new playbooks: align portfolios to affordability realities; localise manufacturing to win tenders and accelerate access; and modernise distribution and digital channels—moves already reshaping strategies in Saudi Arabia, Egypt, and North Africa.
In this analysis, our Healthcare & Life Sciences team examines where growth is concentrating, what is changing in access and infrastructure, and how localisation, distribution upgrades, and digital channels can unlock scale. We've synthesised regional policy shifts, tender dynamics, and manufacturing advances into five pragmatic actions to help biopharma leaders compete and win across developing markets.
The Next Growth Curve
How Biopharma Can Win in Developing Markets
Biopharma’s next growth curve is unfolding across the Middle East and Africa—where 2025 delivered the world’s biggest pharma expansion and “pharmerging” markets are set to add $121B in medicine spending by 2030. Yet success hinges on solving affordability and access, localizing manufacturing to win tenders, and modernizing distribution and digital channels. See how Saudi Arabia’s push toward 70% local spend, Egypt’s export ambitions, and advances in modular biomanufacturing are reshaping go-to-market—and the five moves that will separate winners from the pack.
Emerging markets are redefining biopharma’s growth trajectory—but leadership will hinge on disciplined execution. Companies that focus portfolios on cost-effective innovation, localise to win tenders and accelerate access, upgrade specialty distribution, digitise patient pathways, and build regional hubs will be best positioned to convert headroom into durable share gains.
The window is open: demand is expanding, policy is enabling, and technology is lowering the barriers to scale. The next step is action—prioritise the five moves, sequence them market-by-market, and mobilise cross-functional teams to deliver results on the ground.
Get in touch with our experts
